Why Most Vitamin D Studies Are Misleading
Vitamin D research has a paradox: observational studies tie low levels to nearly every chronic disease, yet the big randomized trials of supplements have mostly come up empty. The article’s argument is that this is largely a design problem, not proof vitamin D is useless — the flagship VITAL trial, for instance, enrolled people whose average blood level was already 30.8 ng/mL (“sufficient”), so extra vitamin D had little room to help, and benefits did appear when researchers looked only at deficient participants. Other distortions include reverse causation (illness lowers vitamin D rather than the reverse) and doses too low to move outcomes. The practical takeaway is to read vitamin D headlines as a question of who was studied: correcting a real deficiency is worthwhile, but supplementing people who are already replete should not be expected to prevent disease.
The large randomized trials designed to test whether vitamin D supplements prevent major chronic diseases have been mostly disappointing — even though observational studies tie low levels to almost all of them. The reason is not that vitamin D doesn’t work. It’s that most trials were designed in ways that almost guarantee a null result, and the flaws below explain how.
Flaw 1: Enrolling people who weren’t deficient
The largest and most cited vitamin D trial is VITAL (Manson 2019, PMID 30415629): 25,871 adults, 2,000 IU/day of vitamin D3 vs. placebo, about 5.3 years of follow-up. VITAL found no significant drop in heart disease or cancer in the overall group. But the average baseline 25(OH)D level was already 30.8 ng/mL — right at the threshold most clinicians call “sufficient.” Giving extra vitamin D to people who are not low has no clear reason to help. When researchers looked only at participants with baseline deficiency, some outcomes did improve. VITAL was a population trial, not a deficiency-correction trial — and the difference matters.
The design flaws that inflate — or erase — effects
Flaw 2: Doses too low to matter
Many early vitamin D trials used 400–800 IU/day. We now know those doses barely move serum 25(OH)D in adults who start out low. The blood levels linked to benefit in observational studies often sit above 40–60 ng/mL, which usually takes 2,000–5,000 IU/day in real-world dosing. Pooled meta-analyses, including the cancer-mortality analysis by Keum et al. 2019 (Annals of Oncology, PMID 31504112), find clearer effects when trials actually push serum levels into the target range.
Flaw 3: Trials are too short
Cancer and heart disease take decades to develop. A 2–3 year supplement trial is usually too short to see a change in cancer rates or heart attacks — even when the underlying biology is real. VITAL’s 5-year follow-up is among the longest, and that may still be too brief for outcomes with a 10–20 year lag. Notably, the VITAL extended follow-up (Bischoff-Ferrari 2022, PMID 35139361) found a 22% drop in autoimmune disease incidence with longer follow-up — an effect the original 5-year analysis missed.
What the better evidence shows
When trials correct these design flaws — enrolling deficient people, using doses that actually raise serum levels, and following participants long enough — the picture improves. The D2d trial (Pittas 2019, PMID 31173679) found that vitamin D in prediabetic adults with baseline 25(OH)D below 12 ng/mL cut progression to type 2 diabetes by 62%. Recent meta-analyses on falls and fractures show benefit only when baseline deficiency is corrected. The big-trial “vitamin D doesn’t work” headline is misleading. The biology is still plausible; most trials are just poorly built to detect it. Bottom line: test, then treat. Don’t supplement blind, and don’t dismiss vitamin D based on null trials in already-replete people.
Sources
- Manson JE, et al. “Vitamin D supplements and prevention of cancer and cardiovascular disease.” New England Journal of Medicine, 2019. PMID 30415629.
- Pittas AG, et al. “Vitamin D supplementation and prevention of type 2 diabetes (D2d).” NEJM, 2019. PMID 31173679.
- Keum N, et al. “Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials.” Annals of Oncology, 2019. PMID 31504112.
- Bischoff-Ferrari HA, et al. “Vitamin D supplements and prevention of autoimmune disease (VITAL extension).” BMJ, 2022. PMID 35139361.
- Scragg R, et al. “Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the Vitamin D Assessment Study (VIDA): a randomized clinical trial.” JAMA Cardiology, 2017. PMID 28384800.